Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioNotebook: Ten deals and a breakup; Gilead/Ono, Vernalis/Novartis, Sorrento/NantWorks and more

This article was originally published in Scrip

Executive Summary

Gilead licenses Ono BTK Inhibitor; Novartis stops developing Vernalis drug; Sorrento partners with NantWorks, Conkwest; Xencor, Novo enter discovery collaboration; ContraVir licenses Chimerix antiviral; MiNa accesses Marina technology; Bayer takes second X-Chem program; Durect grants rights to Santen; Adapt licenses Lightlake's intranasal treatment; and Oncothyreon expands deal with Array.

You may also be interested in...



Novartis Deal Gives Xencor $150m Up Front, Up To $2.41bn In Milestone Fees

Monrovia, California-based Xencor Inc.'s latest collaboration, which is worth $150m up front and up to $2.41bn in milestone fees from Novartis AG, shows how the company is growing up as its research and development pipeline matures.

Finance Watch: Biopharma VC Explosion Extends To Tools, Services

Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.

Roche’s COVID-19 Collaboration Strategy Sees Promise In Combinations

Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.

Topics

Related Companies

UsernamePublicRestriction

Register

OM006664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel